What is the most appropriate drug to lower resting heart rate?

Best Drug to Reduce Resting Heart Rate

Beta-blockers (specifically atenolol or metoprolol) are the most effective drugs for reducing resting heart rate, achieving reductions of 13-19 beats per minute, and are the first-line recommendation in current guidelines.

Guideline-Based Recommendations

The 2024 ESC guidelines for atrial fibrillation provide the most current framework for heart rate reduction 1:

For Patients with Reduced Ejection Fraction (LVEF ≤40%)

• Initiate beta-blocker or digoxin (Class I recommendation)
• Beta-blockers are preferred as first-line agents
• Target: resting heart rate <110 bpm (lenient control), with stricter control if symptoms persist

For Patients with Preserved Ejection Fraction (LVEF >40%)

• Initiate beta-blocker, digoxin, diltiazem, or verapamil (Class I recommendation)
• Beta-blockers remain the preferred initial choice
• Same heart rate targets apply

If Initial Therapy Fails

• Combination therapy: beta-blocker with digoxin, avoiding bradycardia (Class IIa) 1
• For preserved EF: continue or combine beta-blocker, digoxin, diltiazem, or verapamil

The 2014 AHA/ACC/HRS guidelines reinforce this approach, specifically recommending beta-blockers or non-dihydropyridine calcium channel antagonists for heart rate control in heart failure with preserved ejection fraction 2.

Magnitude of Heart Rate Reduction

A comprehensive meta-analysis quantifies the actual heart rate reductions achieved by different agents 3:

Most Effective:

• Atenolol: -19.0 bpm (95% CI: -20.4 to -17.6)
• Metoprolol: -13.2 bpm (95% CI: -14.7 to -11.7), with greater reductions at 150 mg/d
• Ivabradine: -9.3 to -19.6 bpm depending on dose

Moderately Effective:

• Diltiazem: -8.0 bpm at 360 mg/d; sustained-release formulation: -4.5 bpm
• Verapamil: -3.2 bpm (95% CI: -5.1 to -1.3)

Clinical Algorithm for Drug Selection

Step 1: Assess cardiac function

• If LVEF ≤40% → Beta-blocker (atenolol or metoprolol) or digoxin
• If LVEF >40% → Beta-blocker preferred, but diltiazem/verapamil acceptable

Step 2: Consider comorbidities

• Heart failure with reduced EF → Avoid non-dihydropyridine calcium channel blockers (Class III: Harm) 2
• Decompensated heart failure → Avoid IV beta-blockers and calcium channel blockers (Class III: Harm) 2
• Preserved EF with heart failure → Beta-blocker or non-dihydropyridine calcium channel antagonist acceptable

Step 3: Dose titration

• Start with standard doses and titrate based on response
• Metoprolol shows dose-dependent effects with greater reductions at 150 mg/d 3

Step 4: If inadequate response

• Add digoxin to beta-blocker (Class IIa) 1
• Avoid combining beta-blockers with diltiazem/verapamil except under specialist supervision with ambulatory ECG monitoring 1

Important Caveats

Diltiazem's heart rate-regulating effect: Unlike beta-blockers, diltiazem demonstrates a "regulating" rather than purely "lowering" effect—it reduces tachycardia (HR ≥85 bpm) significantly but has minimal effect when baseline HR is ≤74 bpm, avoiding excessive bradycardia 4. This makes it safer in patients with variable heart rates but less effective for consistent rate reduction.

Baseline heart rate matters: All drugs except prazosin reduce heart rate when baseline is ≥85 bpm, but only atenolol achieves further reduction when baseline HR is ≤65 bpm 5. This suggests beta-blockers are more universally effective across all baseline heart rates.

Avoid dihydropyridine calcium channel blockers: These agents (amlodipine, nifedipine) tend to increase heart rate and should not be used for rate control 4.

Ivabradine as alternative: While ivabradine achieves comparable heart rate reduction to beta-blockers through selective If-channel inhibition 6, it lacks the extensive guideline support and broader cardiovascular benefits of beta-blockers, making it a second-line option when beta-blockers are contraindicated or not tolerated.